Advanced Search

 

Study ID Status Title Patient Level Data
25000/593 Completed A randomized open label, 4 period, crossover study to determine the bioequivalence of scored tablets of pharmacokinetically enhanced AUGMENTIN (administered as two tablets which have been broken in half) to unscored whole tablets of pharmacokinetically enhanced AUGMENTIN in healthy volunteers. Study Listed on ClinicalStudyDataRequest.com
25000/600 Completed A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125mg Twice Daily Versus Oral Augmentin 875/125mg Twice Daily for 7 days in the Treatment of Adults with Bacterial Community Acquired Pneumonia. Study Listed on ClinicalStudyDataRequest.com
25000/601 Completed A Study to Determine the Bioequivalence of Reformulated Augmentin Suspension (improved stability) to Standard Marketed Suspension. Study Listed on ClinicalStudyDataRequest.com
25000/611 Completed A Randomized, Investigator-Blind, Multicenter Study to Assess the Efficacy of Oral AUGMENTIN ES-600 Twice Daily for 10 Days Versus Oral Zithromax Once Daily for 5 Days in the Treatment of Acute Otitis Media in Infants and Children. Study Listed on ClinicalStudyDataRequest.com
25000/620 Completed A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125mg Twice Daily Versus Oral Augmentin 875/125mg Three Times Daily for 7 or 10 Days in the Treatment of Adults with Community Acquired Pneumonia of Suspected Pneumococcal Origin. Study Listed on ClinicalStudyDataRequest.com
25000/627 Completed A randomized, double-blind, multicentre, parallel group study to assess the efficacy and safety of oral Augmentin SR 2000/125mg twice daily for 5 days versus a 7-day regimen in the treatment of acute exacerbation of chronic bronchitis Study Listed on ClinicalStudyDataRequest.com
25000/630 Completed A randomised, double-blind, double-dummy, multicentre, parallel group study to assess the efficacy and safety of oral Augmentin SR 2000/125mg twice daily for 5 days versus oral Augmentin 875/125mg twice daily for 7 days in the treatment of adults with acute exacerbations of chronic bronchitis. Study Listed on ClinicalStudyDataRequest.com
25000/643 Completed A bioequivalence study to compare the currently marketed formulation of augmentin with the ES 600 Strawberry Cream Suspension (4A) Study Listed on ClinicalStudyDataRequest.com
25000/665 Completed An open-label, randomized, period balanced, replicate, four-period crossover bioequivalence study comparing AUGMENTIN ES-600 strawberry cream formulation to the marketed suspension. Study Listed on ClinicalStudyDataRequest.com
257049/026 Completed A study to evaluate the safety, immunogenicity and efficacy of GlaxoSmithKline Biologicals’ candidate malaria vaccine RTS,S/AS02A, administered intramuscularly according to a 0, 1 and 2 month vaccination schedule in toddlers and children aged 1 to 4 years in a malaria-endemic region of Mozambique. Study Listed on ClinicalStudyDataRequest.com
263855/004 Completed Randomised clinical study of the consistency of three lots of SB Biologicals dTpa vaccine in terms of immunogenicity and reactogenicity, and of the immunogenicity and reactogenicity of SB Biologicals pa vaccine and Lederle’s Td vaccine when administered as a booster dose to healthy adolescents (10-14 years old)
263855/017 Completed Open, five-year immunogenicity follow-up of subjects who previously received GSK Biologicals dTpa vaccine or GSKBiologicals pa vaccine and Lederles Td vaccine at 10 to 14 years of age in study 263855/004 (EXT: dTpa-004) Study Listed on ClinicalStudyDataRequest.com
263855/019 Completed Open, non-randomized, phase IV study to evaluate immunogenicity and safety of GSK Biologicals’ dTpa vaccine when administered as single dose to healthy adolescents in their 11th to 18th year of life who were not previously vaccinated against pertussis and have anti-PT antibody titers < 20 EL.U/ml  Study Listed on ClinicalStudyDataRequest.com
263855/020 Completed An open, phase III, single center study to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals’ dTpa vaccine administered as a single-dose booster in healthy adults aged ≥ 18 years. Study Listed on ClinicalStudyDataRequest.com
263855/028 Completed Single-blind, randomized, phase IV clinical trial to compare the immunogenicity of GSK Biologicals’ dTpa vaccine (Boostrix™) and Aventis Pasteur MSD’s tetanus toxoid vaccine (Tetavax®), ten days after vaccination of healthy adults 18 years of age and older Study Listed on ClinicalStudyDataRequest.com
263855/029 Completed Observer-blind, randomized, phase II clinical trial to assess the immunogenicity and safety of one dose of three formulations of GSK Biologicals’ dTpa vaccine containing 0.5 mg, 0.3 mg and 0.133 mg of aluminum, respectively in healthy adolescents aged 10 to 18 years Study Listed on ClinicalStudyDataRequest.com
263855/033 Completed Double-blind, randomised phase IIIb, study to compare the immunogenicity and reactogenicity of GSK Biologicals DTPa vaccine (Infanrix™) with GSK Biologicals dTpa (Boostrix™) administered to healthy children 4-6 years of age, having experienced an injection site reaction following the 4th dose of Infanrix™ vaccine Study Listed on ClinicalStudyDataRequest.com
263855/034 Completed Double-blind, randomized, phase III clinical trial to evaluate the immunogenicity and reactogenicity of three consecutive doses of dTpa, or of dTpa-IPV followed by two doses of Td vaccine , and compared to three consecutive doses of Td vaccine administered to healthy adults in a 0,1,6-month schedule Study Listed on ClinicalStudyDataRequest.com
263855/035 Terminated Phase IIIb study to evaluate immunogenicity, antibody persistency and reactogenicity of DTPa - INFANRIX and dTpa - BOOSTRIX vaccines administered to healthy children previously primed with 3 doses of DTPa vaccine compared to placebo (HAVRIX®JUNIOR) Study Listed on ClinicalStudyDataRequest.com
263855/036 Completed Open, phase IIIb, multicentric, safety and reactogenicity study of GSK Biologicals’ reduced antigen content combined diphtheria-tetanus-acellular pertussis vaccine administered as a booster dose to healthy children according to the international recommended prescribing information Study Listed on ClinicalStudyDataRequest.com
275833/030 Completed Protocol SB-275833/030 – Studies 030A and 030B: Two Identical Double-blind, Double-dummy, Multicenter, Comparative Phase III Studies of the Safety and Efficacy of Topical 1% SB-275833, Applied Twice Daily, versus Oral Cephalexin, 500mg in Adults, or 12.5mg/kg (250mg/5ml) in Children, Twice Daily, in the Treatment of Uncomplicated Secondarily Infected Traumatic Lesions (SITL). Study Listed on ClinicalStudyDataRequest.com
275833/032 Completed A Randomized, Double-blind, Double-Dummy, Multicenter, Non-inferiority Phase III Study to Assess the Safety and Efficacy of Topical SB-275833 Ointment, 1%, Applied Twice Daily Study Listed on ClinicalStudyDataRequest.com
29060/006 Completed A study to assess the effectiveness and tolerance of paroxetine by double-blind comparison with placebo Study Listed on ClinicalStudyDataRequest.com
29060/009 Completed A Multicenter, Double-blind, Placebo-controlled Fixed-dose Evaluation of Four Doses of Paroxetine Study Listed on ClinicalStudyDataRequest.com
29060/01/001 Completed A Phase II, Placebo-Controlled, Double-Blind Study of Paroxetine in Depressed Outpatients Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.